GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis (NCT07617155) | Clinical Trial Compass
Not Yet RecruitingPhase 4
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
China396 participantsStarted 2026-09
Plain-language summary
Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is associated with a high risk of recurrence despite standard lipid-lowering therapy and lifestyle modification. The goal of this clinical trial is to evaluate whether GLP-1 receptor agonist therapy can reduce the recurrence of HTG-AP in adults with a history of HTG-AP and hypertriglyceridemia.
The main questions this study aims to answer are:
* Whether GLP-1 receptor agonist therapy reduces the recurrence rate of HTG-AP.
* Whether GLP-1 receptor agonist therapy improves triglyceride control, body weight, and metabolic parameters.
* Whether GLP-1 receptor agonist therapy is safe and well tolerated in this patient population.
Researchers will compare GLP-1 receptor agonist therapy plus standard care with standard care alone to determine whether GLP-1 receptor agonist therapy provides additional benefit in preventing recurrent HTG-AP.
Participants will:
* Receive either GLP-1 receptor agonist therapy plus standard care or standard care alone.
* Undergo regular clinical follow-up visits and laboratory assessments.
* Receive monitoring of triglyceride levels, recurrence events, metabolic outcomes, and adverse events during the study period.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
* Age ≥ 18 years old
* Previous diagnosis of index HTG-AP (defined as AP with serum TG \>1000 mg/dL or a serum TG level of 500-1000 mg/dL accompanied by chylous serum)36-38
* Having HTG as the exclusive cause of AP
* Time from discharge of index HTG-AP to recruitment between 4 weeks to 3 months, without AP-related symptoms between discharge and recruitment
* Expression of the willingness to comply with lifestyle modification during the study period.
* Clinically stable at the time of inclusion
* The ability to understand the trial and completing it, as evaluated by the investigators.
* Patients who may get pregnant should ensure using contraceptives for 20 months after inclusion Exclusion Criteria
* History of malignancy in past 5 years
* History of hypothyroidism, nephrotic syndrome, Cushing's syndrome or AIDS
* History of chronic pancreatitis or pancreatic neoplasm
* History of severe cardiovascular and pulmonary diseases, such as heart failure, coronary heart disease and chronic obstructive pulmonary disease.
* Severe renal deficiency (glomerular filtration rate \< 30 ml/min)
* Severe hepatic deficiency (Child-Pugh Class B or C)
* Previous pancreatic surgery
* Recurrent AP due to pancreatic diverticulum
* Recurrent AP due to known genetic mutations (eg. CFTR)
* Personal or family history of medullary thyroid carcinoma (MTC)
* Current or prior diagnosis or suspected diagnosis of multiple endocrine neoplasia type 2 (MEN2)
* Serious hypersensitivity reacti…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Proportion of participants with recurrent hypertriglyceridemia-induced acute pancreatitis